Document:

Exhibit 10.2

 

MANUFACTURING,
DISTRIBUTION AND SALES AGREEMENT

 

Dated
as of November 2, 2020

 

This
Manufacturing, Distribution and Sales Agreement (this “Agreement”) is entered into on the date first set forth above
(the “Effective Date”) by and between 27 Health, Inc. (“27 Health”), a Delaware corporation and a wholly
owned subsidiary of Lord Global Corporation, a public Nevada corporation (“Lord Global”) and NutraLife Biosciences,
Inc., a Florida corporation (“NutraLife”). Lord Global and 27 Health may be referred to collectively, as the “Company”
and, together with NutraLife, may be referred to collectively, as the “Parties” and individually, be as a “Party.”

 

WHEREAS,
the Company has exclusive world-wide rights to manufacture and market certain products (the “Rights”) including the
product(s) listed on Exhibit A as may be amended form time to time (the “Coviguard Products”) pursuant to the terms
of a Joint Investment and Marketing Agreement dated June 19, 2020 between 27 Health and Coviguard Corp., a Florida corporation
(“Coviguard”);

 

WHEREAS,
27 Health has the exclusive rights to commercially exploit certain brands and trademarks related to the Coviguard Products (together
with such other products, brands, trademarks and trademark rights that 27 Health may create or acquire in the future (collectively,
the “New Products/Brands”); and

 

WHEREAS,
in accordance with the terms of this Agreement, 27 Health desires to engage NutraLife to manufacture the Coviguard Product(s);
and

 

WHEREAS,
in addition, 27 Health desires that NutraLife be granted the right on a non-exclusive basis to sell and distribute (collectively,
“Market”) the Coviguard Products manufactured by NutraLife pursuant to the terms of this Agreement though all channels
of distribution on a worldwide basis (the “Territory”) and to undertake such advertising and marketing as determined
to be necessary by NutraLife with written notice in connection therewith and subject to the terms and conditions herein.

 

NOW,
THEREFORE, in consideration of the foregoing premises and the respective agreements, covenants, representations, warranties and
conditions herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the Parties hereby agree as follows:

 

Article
I. Manufacturing

 

Section
1.01Manufacture and Supply of Products.

 

	 	(a)	During
    the Term (as defined below), NutraLife shall manufacture and supply the Coviguard Products in accordance with specifications
    contained in one or more purchase orders (each, a “PO” or “Purchase Order” ) to be delivered by 27
    Health to NutraLife in form and substance as agreed to by the Parties, subject to the execution of all Purchase Orders by
    27 Health and NutraLife. Furthermore, as provided in Article II, that the Parties acknowledge and agree that NutraLife, in
    addition to manufacturing to Coviguard Products, may directly sell and distribute (collectively, “Market”) the
    Coviguard Products on a non-exclusive basis worldwide.

 

    	1

     

    

 

	 	(b)	In
    the event of a conflict between the terms of this Agreement and the terms of a PO, the terms and conditions in each PO shall
    control.
	 	 	 
	 	(c)	Each
    PO shall be for a minimum quantity of Products as set forth in Exhibit A attached hereto, in the column entitled “Minimum
    Order Quantity.” The Parties agree that the PO’s may be amended from time to time, as the Parties may agree.
	 	 	 
	 	(d)	Upon
    acceptance of a PO countersigned by 27 Health, NutraLife shall manufacture and supply the Products to 27 Health in accordance
    with this Agreement, in compliance with applicable laws and regulation, and using generally accepted industry practice, unless
    27 Health shall elect to have NutraLife Market the Coviguard Products manufactured by NutraLife pursuant to each PO.
	 	 	 
	 	(e)	During
    the Term, NutraLife shall have the exclusive right to manufacture the Coviguard Products subject to the terms of each PO and
    subject to NutraLife’s continued ability to meet in all material respects the production requirements of 27 Health for
    the Coviguard Products. In the event that NutraLife is unable, in the sole determination of 27 Health, to meet said production
    requirements of 27 Health, 27 Health may: (i) seek other sources for manufacture of the Coviguard Products; or (ii) terminate
    this Agreement as provided in Article V, Section 5.02 below.

 

Section
1.02Payment.

 

	 	(a)	27
    Health will pay to NutraLife the per-unit price for the Coviguard Products as set forth on Exhibit A in the column entitled
    “Price to 27 Health” for each unit of the Coviguard Products manufactured for and delivered by NutraLife to 27
    Health, with the understanding that NutraLife will not deliver to 27 Health any Coviguard Products that NutraLife Markets
    under this Agreement.
	 	 	 
	 	(b)	The
    Parties agree that an amount equal to 50% of the total amount of each PO shall be paid by 27 Health to NutraLife upon execution
    and acceptance of the each PO by 27 Health and NutraLife, with the balance due upon completion of the manufacture of the Products
    and prior to such Products being shipped either to 27 Health or to the third-party purchasers of the Coviguard Products which
    NutraLife shall Market, which balance due shall be paid by 27 Health, in the event that 27 Health directs NutraLife to deliver
    the Coviguard Products to 27 Health or by the third-party purchaser in the event that NutraLife directly Markets the Coviguard
    Products, on a case by case basis. In the event that final payment is not made by 27 Health with respect to those Coviguard
    Products delivered to 27 Health in a timely manner, 27 Health will pay interest on any such late payments at the lesser of
    1% per month or the maximum rate permitted by applicable law.

 

Section
1.03Shipments. The Coviguard Products delivered by NutraLife to 27 Health in accordance with the agreed-upon terms
and delivery schedule in accordance with those Purchase Orders providing for delivery to 27 Health will be suitably packaged in
accordance with the respective Purchase Orders. 27 Health will pay for all freight, insurance and other shipping expenses and
title and risk of loss will pass to 27 Health upon delivery of the Coviguard Products and receipt thereof by 27 Health. NutraLife
will use commercially reasonable efforts to deliver the Products on the agreed-upon delivery dates and notify 27 Health in writing
of any anticipated delays. Notwithstanding the foregoing, this Section 1.03 shall not apply to Coviguard Products which NutraLife
shall Market, as provided in Article II.

 

    	2

     

    

 

Section
1.04Product Acceptance. The Coviguard Products delivered by NutraLife to 27 Health will be inspected and tested by
27 Health within three (3) days of receipt of delivery. If the delivered Coviguard Products do not comply with the specifications
in the PO, 27 Health has the right to reject the non-conforming Coviguard Products with written notice to NutraLife. Coviguard
Products not rejected within three (3) days of delivery will be deemed to be accepted by 27 Health. In the event any Coviguard
Products do not comply with the specifications in the PO and are rejected by 27 Health, it may, at its option, return the Coviguard
Products to NutraLife or elect to retain the Coviguard Products notwithstanding such non-conformance, in which latter event 27
Health shall remain required to pay for the Coviguard Products as set forth in Section 1.02.

 

Section
1.05Warranties. NutraLife warrants that it will perform and fulfill each PO in a good, professional and workmanlike
manner, and NutraLife will promptly notify 27 Health of any delay or defect in the manufacture and supply of the Coviguard Products.
NutraLife warrants that the Coviguard Products will be manufactured and supplied in compliance with the specifications in the
PO and in compliance with all governmental and environmental regulations, among other rules and statutes applicable to similar
products intended for human use. NutraLife warrants that the Coviguard Products will be free from substantive defects in workmanship
for a period of thirty (30) from the date of delivery of the shipment either to 27 Health or the third-party customer, as the
case may be.

 

Section
1.06The warranty does not apply to any Coviguard Products that are damaged due to the misuse, abuse, alteration or negligence
of 27 Health, 27 Health’s customers or third-party customers to whom NutraHealth shall Market the Coviguard Products. NutraLife
MAKES NO OTHER REPRESENTATIONS OR WARRANTIES, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO THE COVIGUARD PRODUCTS AND EXPRESSLY
DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

 

Article
II. Distribution.

 

Section
2.01Grant of Rights.

 

	 	(a)	Subject
    to the terms and conditions hereof, NutraLife may elect to Market the Coviguard Products directly, without any requirement
    for a PO being delivered by 27 Health or accepted by NutraLife (each, a “Direct Sale”).
	 	 	 
	 	(b)	In
    connection with any Direct Sales, 27 Health hereby grants to NutraLife the right to distribute the Products through all channels
    of distribution, including, without limitation, via websites, in-person sales, and any and all other channels, in the Territory.
    27 Health shall not modify the Coviguard Products from their specifications as of the Effective Date, other than as required
    to remain in compliance with applicable law, or as agreed to by 27 Health and NutraLife.
	 	 	 
	 	(c)	The
    Parties acknowledge and agree that 27 Health may work at present or in the future with other salespersons and other distributors
    with respect to the Coviguard Products, and that NutraLife’s rights hereunder with respect to the Direct Sales are not
    exclusive, other that as set forth herein.

 

    	3

     

    

 

Section
2.02Payments for Direct Sales.

 

	 	(a)	All
    Direct Sales shall be made by NutraLife to the recipient of the Products (“Buyer”) at or below the manufacturer’s
    suggested retail price as set forth on Exhibit A in the column entitled “MSRP”, and otherwise on terms and schedules
    as agreed to by NutraLife and applicable purchaser thereof.
	 	 	 
	 	(b)	Upon
    receipt from the Buyer for a Direct Sale, NutraLife shall pay to 27 Health an amount equal to (i) the “Distributor Price”
    as set forth on Exhibit A as applicable to such Direct Sale, less (ii) the total “Price to 27 Health” as set forth
    on Exhibit A as applicable to such Direct Sale. By way of example and not limitation, in the event that the MSRP for a unit
    of a Product is $3.25, the Distributor Price is $3.00 and the Price to 27 Health is $1.25, for each unit of such Product sold
    to a Buyer, NutraLife would pay to 27 Health the sum of $1.75 ($3.00 minus $1.25), and NutraLife shall be entitled to retain
    the balance of $1.50 (MSRP of $3.25 less then amount paid to 27 Health).

 

Section
2.03Process of Direct Sales. All Direct Sales shall be handled as between NutraLife and the applicable Buyer, without
any involvement of 27 Health being required, provided that NutraLife shall provide at least quarterly written updates with respect
to the Direct Sales, including the Buyers, amounts sold and payments made and an accounting of the required payments due and paid
to 27 Health.

 

Article
III. Sales Leads.

 

Section
3.01Identification of Customers.

 

	 	(a)	In
    the event that NutraLife identifies a potential third-party customer (collectively, the “Customers” and individually,
    a “Customer”) for the Coviguard Products, but does not elect to sell the Coviguard Products directly to such Customer
    pursuant to Article II, which election NutraLife may make in its sole discretion, NutraLife may refer such potential Customer
    to 27 Health and shall provide 27 Health with information with respect to the identity of the potential Customer. 27 Health
    will then inform NutraLife as to whether or not 27 Health or any of its Affiliates (as defined below), Representatives (as
    defined below) or agents (each a “27 Health Party” and collectively, the “27 Health Parties”) are
    currently selling any Coviguard Products to such potential Customer(s) as of such time.
	 	 	 
	 	(b)	In
    the event that any 27 Health Party is currently selling any Coviguard Products to such potential Customer(s) as of such time,
    as shown by reasonable evidence provided to NutraLife is so requested (such as completed purchase orders, etc.), then such
    potential Customer(s) shall be termed an “Existing Customer” or “Existing Customers”).
	 	 	 
	 	(c)	In
    the event that no 27 Health Party is currently selling any Coviguard Products to such potential Customer(s) as of such time,
    then such potential Customer(s) shall be termed a “NutraLife Customer” or “NutraLife Customers.”
	 	 	 
	 	(d)	Subject
    to the forgoing and the other provisions herein, any references hereby with respect to one or more “Customers”
    shall be deemed a reference to either the Existing Customer or the NutraLife Customer, as applicable.

 

    	4

     

    

 

Section
3.02Sales and Commissions.

 

	 	(a)	No
    payments or commissions shall be due or payable to NutraLife to any sales of Coviguard Products to Existing Customers other
    than the costs to 27 Health for the manufacture by NutraLife of the Coviguard Products under Purchase Orders.
	 	 	 
	 	(b)	All
    sales to NutraLife Customers by 27 Health pursuant to this Article III shall be made at the MSRP for the applicable Coviguard
    Products as set forth on Exhibit A.
	 	 	 
	 	(c)	For
    any and all sales of Coviguard Products to NutraLife Customers pursuant to this Article III, 27 Health shall pay to NutraLife
    commissions in the amount of 15% of the amount actually received by 27 Health with respect to any sales of Coviguard Products
    to NutraLife Customers. Commissions are payable within five business (5) days of 27 Health’s receipt of payment from
    the applicable NutraLife Customers on Coviguard Product sales. Payments will be made by direct deposit to an account as directed
    by NutraLife in writing.
	 	 	 
	 	(d)	The
    payments of commissions pursuant to this Section 3.02 shall be in addition to any payments due to NutraLife pursuant to Article
    I.

 

Article
IV. Additional Covenants and Agreements

 

Section
4.01Applicability. The Parties acknowledge and agree that the provisions of Article I, Article II and Article III shall
be applied independently, and therefore (i) Article II and Article III shall not apply with respect to POs generated by 27 Health
pursuant to Article I, other than POs for the manufacture of Coviguard Products for sale to NutraLife Customers, with respect
to which the provisions of Article III shall apply; (ii) Article I and Article III shall not apply in the event that NutraLife
elects to manufacture and sell Coviguard Products directly pursuant to Article II; and (iii) Article II shall not apply in the
event that NutraLife elects to refer any potential Customers to 27 Health pursuant to Article III, provided that the Parties agree
that Article I shall continue to apply to the manufacture of the Coviguard Products for any such NutraLife Customers.

 

Section
4.02Additional Agreements. In addition to the other provisions herein, the Parties agree that the following shall apply
to the actions of the Parties hereunder:

 

	 	(a)	Product
    Documentation and Supply. 27 Health will provide to NutraLife all necessary supporting documents details relating to the
    Coviguard Products, including specification sheets, detailed material safety data sheets, and all other commercial documents
    required for the sale and distribution of the Coviguard Products.
	 	 	 
	 	(b)	Marketing
    Costs. All trade marketing and advertising costs through NutraLife’s marketing channels with respect to NutraLife’s
    activities pursuant to Article II shall be borne by NutraLife (other than such costs as specifically set forth herein as to
    be paid by 27 Health). Notwithstanding the forgoing, the Parties agree that they may agree as to any other apportionment of
    extraordinary marketing and advertising costs between the Parties, such agreement to be given in the sole discretion of each
    Party. During the Term, 27 Health shall assist the NutraLife as reasonably requested in the NutraLife’s efforts to promote
    and sell the Coviguard Products, provided that, other than the provision of reasonable quantities of free product, support
    materials, and promotional literature, which shall be provided at no charge, NutraLife shall reimburse 27 Health for 27 Health’s
    actual costs related to such assistance.

 

    	5

     

    

 

Section
4.03Customer Service; Product Refunds; Unsalable Products. With respect to any sales of Coviguard Products which are
not manufactured by NutraLife (pursuant to the provisions of Section 1.01(e)) to any Buyer or Customer, 27 Health shall accept
any Coviguard Products which is returned by such Buyer or Customer and shall repurchase from NutraLife at a purchase price equal
to the full purchase price initially paid by NutraLife to 27 Health for such Coviguard Product for (a) any returned Coviguard
Products which are unsalable only as a result of defective production; and (b) any Coviguard Products which are damaged or in
otherwise an unsalable condition upon their delivery to NutraLife or the end Customer or Buyer (including, without limitation,
as a result of any damaged master shippers and cartons). 27 Health will not reimburse NutraLife for any state, local or municipal
excise tax stamps affixed to returned unsalable Coviguard Products, unless these Coviguard Products are deemed unsalable due to
production defects. Coviguard Product’s unsalable condition will be reviewed, determined and confirmed by 27 Health, and
any applicable refunds will be issued upon 27 Health’s review and determination.

 

Section
4.04Alternate Manufacturers. In the event that the provisions of Section 1.01(e) are applicable, and an alternate manufacturer
is engaged by 27 Health to manufacture any Coviguard Products which are then distributed by NutraLife, the Parties shall reasonably
cooperate to amend this Agreement to reflect such alternate manufacturer so as to provide the Parties with substantially the same
economic and operational results as though the Coviguard Products remained manufactured by NutraLife.

 

Section
4.05Recall. In the event 27 Health believes that it may be necessary to conduct a field correction, market withdrawal,
stock recovery, or other similar action with respect to any Product (collectively defined as a “Recall”), 27 Health
shall have sole authority with respect to such Recall and the Parties shall work together to safely and effectively conduct such
Recall as quickly and efficiently as possible. NutraLife shall provide the 27 Health with reasonable access to those Customers
of NutraLife affected by the Recall, to the extent practicable, and all information received or compiled by NutraLife from such
Customers or otherwise with respect to such Recall, except as otherwise prohibited by Law. 27 Health shall be responsible for
the costs and expenses of any Recall.

 

Section
4.06Annual Amendment. The Parties shall meet at least annually in the fourth calendar quarter of each year, commencing
in the fourth quarter of calendar year 2021, to review and discuss the Coviguard Products and pricing as set forth on Exhibit
A, provided that such review may also be completed at any other times as determined by the Parties. At such times, the Parties
may, each in their sole discretion, agree to remove, to the extent applicable, one or more Coviguard Products from Exhibit A,
to add certain Coviguard Products to Exhibit A or to amend any other items as set forth on Exhibit A, provided that any such amendments
shall not apply to any Coviguard Products for which a Purchase Order (as defined above) has already been submitted to 27 Health,
even if not fulfilled at such time.

 

Section
4.07Brands. 27 Health hereby grants NutraLife the right to use the Brands, the name of 27 Health and Coviguard and
any other intellectual property with respect to which 27 Health has exclusive manufacturing, sales and distribution rights under
its Joint Investment and Marketing Agreement dated June 19, 2020 between 27 Health and Coviguard, solely in connection with the
exercise of NutraLife’s rights and the enforcement of 27 Health’s obligations in accordance with the terms hereof.
27 Health shall provide NutraLife with any updates of its packaging, instructions, manuals, catalogues and other printed materials
(including, without limitation, advertising materials) relating to the Coviguard Products, if any, within fifteen (15) calendar
days of such printed materials becoming available for use. NutraLife shall notify 27 Health of any infringements of 27 Health’s
intellectual property rights in the Territory of which NutraLife becomes aware. Prosecution of infringement shall be at 27 Health’s
discretion and cost unless such infringement is caused by NutraLife, in which event the other provisions herein, including Article
VII, shall control. Nonetheless, 27 Health agrees to and will act in good faith to maintain the value of the Brands’ and
Coviguard Products’ respective intellectual property rights. Any damages received shall be credited to 27 Health. NutraLife
shall offer all reasonable assistance to 27 Health in infringement procedures as well as in any other procedure to maintain the
intellectual property rights related to the Coviguard Products, including submission of proof of use.

 

    	6

     

    

 

Section
4.08Public Announcement. The Parties agree that any public announcement relating to the transactions set forth herein
will not be issued containing the name of any Party without express written approval of the other Parties, unless otherwise required
by applicable law. The Parties acknowledge and agree that both Lord Global and NutraLife are publicly traded entities and are
required to release certain information for the purposes of compliance.

 

Section
4.09Compliance with Law. Each Party shall comply with all United States federal, state and municipal securities and
other applicable laws, rules, regulations, standards and orders (collectively, “Applicable Laws”) in connection with
its activities hereunder; provided, however, that 27 Health shall be solely responsible for complying with all other Applicable
Laws with regard to the composition, makeup, development, and manufacture of the Coviguard Products, and 27 Health shall be solely
responsible for complying with all other Applicable Laws with regard to the supply, advertising and marketing of the Coviguard
Products (including, without limitation, any labels affixed to the Coviguard Products and the content of any advertising or marketing
materials relating to the Coviguard Products which are provided to NutraLife by 27 Health), and 27 Health’s license, distribution
and sale of the Coviguard Products to third parties other than NutraLife, and shall indemnify, defend and hold harmless the NutraLife
and the Existing Customers from any liability as a result of the use of the Coviguard Products or any damages resulting therefrom.

 

Section
4.10Compliance with Laws and Regulatory Matters.

 

	 	(a)	General
    Compliance. Each of 27 Health and NutraLife shall be responsible for obtaining and maintaining all governmental registration
    and approvals required for the completion of its obligations hereunder, at such Party’s own expense. The Parties shall
    also at all times comply with all Applicable Laws (as defined above) and follow all generally accepted industry standards
    in accordance with all regulatory agencies, applicable to the sale and distribution of the Coviguard Products and to the operations
    and business of 27 Health and NutraLife throughout the Territory, including without limitation, all Applicable Laws, including
    federal, state and local anti-dumping and consumer protection laws and regulations, among others. The Parties shall procure
    all permits, licenses and insurance (including, without limitation, workers’ compensation or similar coverage) necessary
    or required by any governmental authority to perform its obligations under this Agreement. Each of 27 Health and NutraLife
    shall, upon request by the other Party, promptly provide to the requesting Party written evidence of each and all such compliance
    with Applicable Laws and corresponding regulations.
	 	 	 
	 	(b)	Regulatory
    Matters. Each of the Parties shall comply with all Applicable Laws which are applicable to their respective operations,
    duties and obligations hereunder.

 

    	7

     

    

 

Section
4.11Regulatory Assistance and Inquiry. Each Party agrees to cooperate, as reasonably requested by the other Party,
to assist in obtaining all necessary regulatory approvals to the extent such assistance of the other Party is necessary. The Party
requesting assistance shall bear the reasonable costs and expenses of the complying Party’s cooperation. Each Party shall
promptly and in any event within fifteen (15) days after receipt of any notice of inquiry from any local, state, national or international
regulatory agency or government department, inform the other in writing of such formal or informal inquiry relating to the Coviguard
Products.

 

Article
V. Term and Termination

 

Section
5.01Term. Subject to earlier termination or extension as provided herein, the term of this Agreement shall commence
upon the Effective Date and shall continue for a five (5) year period (the “Initial Term”). There shall be automatic
(subject to the below) consecutive extensions of the term of this Agreement (each, a “Renewal Term” and, together
with the Initial Term, the “Term”) of one (1) year duration for each Renewal Term. Subject to the terms and conditions
herein, upon the expiration of the Initial Term and any later Renewal Term, the Term shall automatically be renewed for each successive
Renewal Term unless either Party elects not to renew the Initial Term or any renewal term upon written notice to the other Party;
provided, however, that any notice not to renew must be delivered at least thirty (30) days prior to the expiration of the Initial
Term or the Renewal Term, as the case may be.

 

Section
5.02Termination. This Agreement and the Term may be terminated:

 

	 	(a)	At
    any time upon the mutual written agreement of the Parties;
	 	 	 
	 	(b)	by
    either Party upon ten (10) days’ prior written notice to the other Party upon the material breach by the other Party
    of any of its covenants, agreements, representations or warranties set forth in this Agreement, unless such breach is cured
    within such ten (10) days’ notice period; or
	 	 	 
	 	(c)	immediately
    by either Party upon written notice to the other Party upon (i) the discontinuance, dissolution, liquidation and/or winding
    up of the other Party’s business or (ii) the making, by the other Party, of any general assignment or arrangement for
    the benefit of creditors; the filing by or against the other Party of a petition to have it adjudged bankrupt under bankruptcy
    or insolvency laws, unless such petition shall be dismissed or discharged within sixty (60) days; (iii) the appointment of
    a trustee or receiver to take possession of all or substantially all of such Party’s assets, where possession is not
    restored to the appropriate Party within thirty (30) days; or (iv) the attachment, execution or judicial seizure of all or
    substantially all of the other Party’s assets where attachment, execution or judicial seizure is not discharged within
    thirty (30) days; or
	 	 	 
	 	(d)	the
    determination by 27 Health not to proceed with or devote further efforts to the manufacture, marketing, distribution and sale
    of the Coviguard Products pursuant to the a Joint Investment and Marketing Agreement dated June 19, 2020 between 27 Health
    and Coviguard.

 

Section
5.03Effect of Termination. Upon the expiration or earlier termination of this Agreement:

 

	 	(a)	Subject
    to the provisions of Section 5.04, all rights granted to NutraLife under this Agreement shall terminate, and all such rights
    shall revert back to 27 Health.

 

    	8

     

    

 

	 	(b)	In
    the event of a termination of this Agreement for any reason, then, at NutraLife’s election, either (i) 27 Health shall
    repurchase from NutraLife within thirty (30) days of the termination of this Agreement, at a price equal to one hundred percent
    (100%) of the price actually paid to 27 Health by NutraLife for any applicable Coviguard Products manufactured by NutraLife
    in compliance with the quality standards set forth in thePOs, consistuent with ther business practices of the Parties under
    this Agreement, calculated on a FIFO basis, all quantities of the Coviguard Products which are unsold by NutraLife as of the
    effective date of termination; or (ii) NutraLife shall, following any such termination, continue to have a right to sell any
    Coviguard Products then received and paid for by NutraLife. Any Coviguard Products(s) required to be repurchased by 27 Health
    hereunder shall be delivered to 27 Health at a location designated by 27 Health and 27 Health shall be responsible for all
    shipping and associated costs for such return shipment as a result of this Section 5.03(b).

 

Section
5.04Exclusivity and Non-Circumvention for NutraLife Customers.

 

	 	(a)	Except
    as otherwise expressly provided herein, including with respect to any NutraLife Customers, the rights and licenses granted
    under this Agreement are not exclusive to NutraLife. Subject to the terms and conditions herein, 27 Health may utilize any
    other 27 Health Party to distribute any Coviguard Products to any Existing Customer.
	 	 	 
	 	(b)	27
    Health agrees that, during the Term and for a period of two (2) years thereafter (subject to the provisions of Section 5.04(c),
    the “Tail Period”), 27 Health shall not, and shall use its commercially reasonable efforts to cause any 27 Health
    Party not to, (i) contact any NutraLife Customer with respect to the Coviguard Products without the prior notification to
    and approval of NutraLife; (ii) take any actions that would reasonably be expected to result in a sale of Coviguard Products
    to a NutraLife Customer to occur without the involvement or approval of the NutraLife; (iii) directly or indirectly, as an
    owner, officer, director, employee or agent, sell, give or otherwise provide any Coviguard Products to any NutraLife Customer
    or enter into any agreement with NutraLife Customer or any of its Affiliates with respect to the sale and purchase of any
    Coviguard Products without the involvement of and approval of the NutraLife or in any manner that could reasonably be expected
    to reduce, or in any other manner avoid or interfere with, directly or indirectly the profit amounts that would be received
    by NutraLife upon any sales of any Coviguard Products to such NutraLife Customer (and, with respect to the Tail Period, assuming
    that this Agreement had remained in effect as of such time); or (iv) utilize any 27 Health Party to circumvent or attempt
    to circumvent the intent of this Agreement. The Company shall cause each 27 Health Party to comply with the terms of this
    Section 5.04, and the Company shall be responsible for any breach of the terms and conditions hereunder by aby such 27 Health
    Party. Any consent required pursuant to this Section 5.04 may be given or withheld in the sole discretion of the NutraLife.
    The Parties acknowledge and agree that the intent of this Section 5.04(b) is that, among other things, in the event that the
    Tail Period applies, no sales of any Coviguard Products to any NutraLife Customer shall be made unless NutraLife receives
    the profit that it would have made on such sale in the event that such sale had been made during the Term as a result of NutraLife
    marketing efforts. In the event that any such sale in the Tail Period is for a new previously unsold Coviguard Product, the
    Parties shall reasonably agree on what would be a customary profit or commission for such sales of such Coviguard Products.
    The Parties further acknowledge and agree that NutraLife may consent to sales of Coviguard Products to a NutraLife Customer
    by 27 Health or a 27 Health Party during the Tail Period conditioned on customary and reasonable commissions being paid to
    NutraLife with respect to such sales.

 

    	9

     

    

 

	 	(c)	Notwithstanding
    the provisions of Section 5.04(b), in the event that 27 Health terminates this Agreement pursuant to the provisions of Section
    5.02(b) due to a material uncured breach by NutraLife of any of its covenants, agreements, representations or warranties set
    forth in this Agreement, then the Tail Period as set forth in Section 5.04(b) shall not apply and shall be deemed null and
    void following such termination.

 

Article
VI. Representations and Warranties

 

Section
6.01Mutual Representations and Warranties. Each Party represents and warrants to the other Party that the representing
party is an entity duly organized, validly existing and in good standing under the laws of the State of its organization and it
has the complete right, power and authority to enter into this Agreement and the ability, power, and authority to perform all
of its obligations hereunder, and this Agreement constitutes a valid and legally binding obligation of such representing Party,
enforceable against such Party in accordance with its terms except as limited by applicable bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance or other laws of general application relating to or affecting the enforcement of creditors’
rights generally.

 

Section
6.02Representations and Warranties of NutraLife. NutraLife represents and warrants to 27 Health that:

 

	 	(a)	no
    consent or approval is required by any Person for NutraLife to enter into this Agreement or for NutraLife to exercise the
    rights granted hereunder and the execution, delivery and performance by NutraLife of this Agreement and the consummation of
    the transactions contemplated herein do not and will not: (i) conflict with or result in a violation or breach of, or default
    under, any provision of the certificate of incorporation, by-laws or other organizational documents of NutraLife; or (ii)
    conflict with or result in a violation or breach of any provision of any Applicable Law or Governmental Order applicable to
    NutraLife;
	 	 	 
	 	(b)	no
    consent, approval, permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required
    by or with respect to NutraLife in connection with the execution and delivery of this Agreement and the consummation of the
    transactions contemplated herein;
	 	 	 
	 	(c)	there
    are no pending or threatened actions, suits or claims against NutraLife or any of its Affiliates that would impair NutraLife’s
    ability to enter into this Agreement;
	 	 	 
	 	(d)	NutraLife
    is now in compliance in all material respects with all Applicable Laws relating to its business; and
	 	 	 
	 	(e)	NutraLife
    possesses and shall maintain in full force and effect at all times during the term of this Agreement all licenses, permits
    and similar authorizations required for the performance of its obligations hereunder.

 

    	10

     

    

 

Section
6.03Representations and Warranties of 27 Health. 27 Health represents and warrants to NutraLife the following:

 

	 	(a)	no
    consent or approval is required by any Person for 27 Health to enter into this Agreement or for 27 Health to exercise the
    rights granted hereunder and the execution, delivery and performance by 27 Health of this Agreement and the consummation of
    the transactions contemplated herein do not and will not: (i) conflict with or result in a violation or breach of, or default
    under, any provision of the certificate of incorporation, by-laws or other organizational documents of NutraLife; or (ii)
    conflict with or result in a violation or breach of any provision of any Applicable Law or Governmental Order applicable to
    NutraLife;
	 	 	 
	 	(b)	no
    consent, approval, permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required
    by or with respect to 27 Health in connection with the execution and delivery of this Agreement and the consummation of the
    transactions contemplated herein;
	 	 	 
	 	(c)	there
    are no pending or threatened actions, suits or claims against 27 Health or any of 27 Health’s Affiliates (i) relating
    to the Coviguard Products or (ii) that would impair 27 Health’s ability to enter into this Agreement;
	 	 	 
	 	(d)	27
    Health has not entered into any oral or written contract or negotiations with any third parties which would impair the rights
    granted to NutraLife under this Agreement, or limit the effectiveness of this Agreement, nor is it aware of any claims or
    actions which may limit or impair any of the rights granted to NutraLife hereunder; provided that, notwithstanding the prior
    provisions of this Section 6.03(d), the Parties acknowledge and agree that the rights granted to NutraLife under his Agreement
    are non-exclusive and nothing contained herein is intended to preclude 27 Health or a 27 Health Party from marketing and selling
    the Coviguard Products to any Existing Customer or any other third-party customer that is not a NutraLife Customer;
	 	 	 
	 	(e)	other
    than as specifically referenced herein, all intellectual property rights, materials and work product relating to the Coviguard.
    Products are owned by 27 Health and, to 27 Health’s knowledge, do not infringe or violate any copyrights, trademarks,
    trade secrets, patents or other proprietary rights of any kind belonging to any third party or violate any right of privacy,
    right to publicity, misappropriate anyone’s name or likeness or contain any defamatory, obscene or illegal material;
	 	 	 
	 	(f)	27
    Health is now in compliance in all material respects with all Applicable Laws relating to its business and Coviguard Products
    in the Territory; and
	 	 	 
	 	(g)	the
    Coviguard Products sold to NutraLife by 27 Health hereunder will be free and clear of any liens or encumbrances created by
    27 Health.

 

    	11

     

    

 

Article
VII. Indemnification

 

Section
7.01Indemnification by 27 Health. 27 Health shall indemnify, defend and hold NutraLife and its Affiliates, and its
and their respective shareholders, members, managers, directors, officers, agents, employees, and representatives, as the case
may be (collectively, “Representatives”), harmless from and against any and all actual damages, fines, fees, penalties,
liabilities, claims, losses, demands, suits, judgments, awards, settlements, actions, obligations, costs and expenses (including
reasonable costs of attorneys, accountants and other experts or other reasonable expenses of litigation or other Actions (as defined
below) or of any default or assessment (collectively, “Losses”) that are caused by or shall arise out of any of the
following: (i) any product liability claims or claims for property damage, personal injury or death arising from or relating to
any use of the Coviguard Products; (ii) any actions by Persons claiming ownership or other rights in the Coviguard Products or
the intellectual property rights relating thereto other than to the extent caused by the actions of NutraLife; (iii) any actual
or alleged infringement by the Coviguard Products or any intellectual property rights relating thereto, or any advertising materials
with respect thereto, in each case to the extent provided by 27 Health, of any intellectual property rights of any third parties
or misappropriation of any trade secrets of any third parties; (iv) 27 Health’s breach of any representations, warranties,
covenants or agreements contained in this Agreement, unless the Loss arises from the gross negligence of NutraLife or any of its
Representatives; (v) any claims or actions arising out of the failure by 27 Health to comply with any Applicable Laws relating
to the development, manufacturing, advertising, marketing, labeling, distribution or sale of the Coviguard Products (except as
otherwise subject to indemnification by NutraLife in accordance with Section 7.02, (vi) any class actions or governmental or regulatory
investigations, inquiries, or actions relating to 27 Health’s business or the Coviguard Products; or (v) any claim by any
Person for brokerage or finder’s fees or commissions or similar payments based upon any agreement or understanding made,
or alleged to have been made, by any such Person with 27 Health (or any Person acting on its behalf) in connection with any transactions
contemplated herein.

 

Section
7.02Indemnification by NutraLife. NutraLife shall indemnify, defend and hold 27 Health and its Affiliates and its and
their Representatives harmless from and against any and all Losses that are caused by or shall arise out of (i) any claims or
actions arising out of the failure by NutraLife or its Representatives to comply with its obligations hereunder with respect to
any Applicable Laws relating to NutraLife’s distribution of the Coviguard Products in the Territory (except to the extent
any such Losses are caused by or relate to the Coviguard Products or any materials provided or made available by 27 Health or
its contractors and agents to NutraLife); or (ii) NutraLife’s breach of any representations, warranties, covenants or agreements
contained in this Agreement, unless the Loss arises from the gross negligence of 27 Health or any of its Representatives, or (iii)
any claim by any Person for brokerage or finder’s fees or commissions or similar payments based upon any agreement or understanding
made, or alleged to have been made, by any such Person with NutraLife (or any Person acting on its behalf) in connection with
any transactions contemplated herein.

 

Section
7.03Procedures for Indemnification; Defense.

 

	 	(a)	Definition.
    The Person entitled to indemnification under this Article VII is referred to as the “Indemnified Party” and the
    Party obligated to provide indemnification under this Article VII is referred to as the Indemnifying Party”).

 

    	12

     

    

 

	 	(b)	Third-Party
    Claims. If any Indemnified Party receives notice of the assertion or commencement of any legal action, suit, claim, investigation,
    hearing or proceeding, including any audit, claim or assessment for taxes or otherwise (each, an “Action” made
    or brought by any Person who is not a party to this Agreement or an Affiliate of a party to this Agreement or a Representative
    of the foregoing (a “Third-Party Claim”) against such Indemnified Party with respect to which the Indemnifying
    Party is obligated to provide indemnification under this Agreement, the Indemnified Party shall give the Indemnifying Party
    reasonably prompt written notice thereof, but in any event not later than thirty (30) calendar days after receipt of such
    notice of such Third-Party Claim. The failure to give such prompt written notice shall not, however, relieve the Indemnifying
    Party of its indemnification obligations, except and only to the extent that the Indemnifying Party forfeits rights or defenses
    by reason of such failure. Such notice by the Indemnified Party shall describe the Third-Party Claim in reasonable detail,
    shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably practicable,
    of the Loss that has been or may be sustained by the Indemnified Party. The Indemnifying Party shall have the right to participate
    in, or by giving written notice to the Indemnified Party, to assume the defense of any Third-Party Claim at the Indemnifying
    Party’s expense and by the Indemnifying Party’s own counsel, and the Indemnified Party shall cooperate in good
    faith in such defense. In the event that the Indemnifying Party assumes the defense of any Third-Party Claim, subject to Section
    7.03(c), it shall have the right to take such action as it deems necessary to avoid, dispute, defend, appeal or make counterclaims
    pertaining to any such Third-Party Claim in the name and on behalf of the Indemnified Party. The Indemnified Party shall have
    the right to participate in the defense of any Third-Party Claim with counsel selected by it subject to the Indemnifying Party’s
    right to control the defense thereof, provided that the fees and disbursements of such counsel shall be at the expense of
    the Indemnified Party.
	 	 	 
	 	(c)	Settlement
    of Third-Party Claims. Notwithstanding any other provision of this Agreement, the Indemnifying Party shall not enter into
    settlement of any Third-Party Claim without the prior written consent of the Indemnified Party, except as provided in this
    Section 7.03(c). If a firm offer is made to settle a Third-Party Claim without leading to liability or the creation of a financial
    or other obligation on the part of the Indemnified Party and provides, in customary form, for the unconditional release of
    each Indemnified Party from all liabilities and obligations in connection with such Third-Party Claim and the Indemnifying
    Party desires to accept and agree to such offer, the Indemnifying Party shall give written notice to that effect to the Indemnified
    Party. If the Indemnified Party fails to consent to such firm offer within ten days after its receipt of such notice, the
    Indemnified Party may continue to contest or defend such Third-Party Claim and in such event, the maximum liability of the
    Indemnifying Party as to such Third-Party Claim shall not exceed the amount of such settlement offer. If the Indemnified Party
    fails to consent to such firm offer and also fails to assume defense of such Third-Party Claim, the Indemnifying Party may
    settle the Third-Party Claim upon the terms set forth in such firm offer to settle such Third-Party Claim. If the Indemnified
    Party has assumed the defense pursuant to Section 7.03(b), it shall not agree to any settlement without the written consent
    of the Indemnifying Party (which consent shall not be unreasonably withheld or delayed).

 

    	13

     

    

 

	 	(d)	Direct
    Claims. Any Action by an Indemnified Party on account of a Loss which does not result from a Third-Party Claim (a “Direct
    Claim”) shall be asserted by the Indemnified Party giving the Indemnifying Party reasonably prompt written notice thereof,
    but in any event not later than thirty (30) calendar days after the Indemnified Party becomes aware of such Direct Claim.
    The failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations,
    except and only to the extent that the Indemnifying Party forfeits rights or defenses by reason of such failure. Such notice
    by the Indemnified Party shall describe the Direct Claim in reasonable detail, shall include copies of all material written
    evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained
    by the Indemnified Party. The Indemnifying Party shall have thirty (30) calendar days after its receipt of such notice to
    respond in writing to such Direct Claim. The Indemnified Party shall allow the Indemnifying Party and its professional advisors
    to investigate the matter or circumstance alleged to give rise to the Direct Claim, and whether and to what extent any amount
    is payable in respect of the Direct Claim and the Indemnified Party shall assist the Indemnifying Party’s investigation
    by giving such information and assistance as the Indemnifying Party or any of its professional advisors may reasonably request.
    If the Indemnifying Party does not so respond within such thirty (30) calendar day period, the Indemnifying Party shall be
    deemed to have rejected such claim, in which case the Indemnified Party shall be free to pursue such remedies as may be available
    to the Indemnified Party on the terms and subject to the provisions of this Agreement.
	 	 	 
	 	(e)	Cooperation.
    Upon a reasonable request made by the Indemnifying Party, each Indemnified Party seeking indemnification hereunder in respect
    of any Direct Claim, hereby agrees to consult with the Indemnifying Party and act reasonably to take actions reasonably requested
    by the Indemnifying Party in order to attempt to reduce the amount of Losses in respect of such Direct Claim. Any costs or
    expenses associated with taking such actions shall be included as Losses hereunder.

 

Section
7.04Periodic Payments. Any indemnification required by this Article VII for reasonable costs, disbursements or expenses
of any Indemnified Party in connection with investigating, preparing to defend or defending any Action shall be made by periodic
payments by the Indemnifying Party to each Indemnified Party during the course of the investigation or defense, as and when bills
are received or costs, disbursements or expenses are incurred. Once a Loss is agreed to by the Indemnifying Party or finally adjudicated
to be payable pursuant to this Article VII, the Indemnifying Party shall satisfy its indemnification obligations within thirty
(30) calendar days of such agreement or adjudication.

 

Section
7.05Insurance. Any indemnification payments hereunder shall take into account any insurance proceeds or other third-party
reimbursement actually received.

 

Section
7.06Effect of Investigation. The representations, warranties and covenants of the Indemnifying Party, and the Indemnified
Party’s right to indemnification with respect thereto, shall not be affected or deemed waived by reason of any investigation
made by or on behalf of the Indemnified Party (including by any of its Representatives) or by reason of the fact that the Indemnified
Party or any of its Representatives knew or should have known that any such representation or warranty is, was or might be inaccurate.

 

Section
7.07Limitation on Damages. In no event will any Party be liable to any other Party under or in connection with this
Agreement or in connection with the transactions contemplated herein for special, general, indirect, consequential, or punitive
or exemplary damages, including damages for lost profits or lost opportunity, even if the Party sought to be held liable has been
advised of the possibility of such damage.

 

    	14

     

    

 

Article
VIII. Miscellaneous

 

Section
8.01Force Majeure. Neither Party shall be held liable or responsible to the other Party nor be deemed to be in default
under, or in breach of any provision of, this Agreement for failure or delay in fulfilling or performing any obligation of this
Agreement, other than the obligation to make money payments, when such failure or delay is due to a Force Majeure Event (as defined
below), and without the fault or negligence of the Party so failing or delaying. The Party whose performance is affected by a
Force Majeure Event (the “Affected Party”) shall give prompt notice to the other Party stating the details and expected
duration of the event. Once said notice is given, the Parties shall keep each other appraised of the situation until the Force
Majeure Event terminates or this Agreement is terminated, whichever occurs first. If the performance of the Affected Party does
not resume within six (6) months of the occurrence of a Force Majeure Event, the other Party shall have the right to terminate
this Agreement without penalty. “Force Majeure Event” shall mean any event beyond the reasonable control of the Party
affected by such circumstance, including, but not limited to, an act of God, delay or loss in transportation, fire, flood, earthquake,
storm, war, terrorism, riot, revolt, act of public enemy, embargo, explosion, civil commotion, strike, labor dispute, loss or
shortage of power, impossibility of obtaining or shortage in supply of raw materials or finished Product, or any adverse determination
with respect to any law, rule, regulation, or order, or any other action by any third party, public authority, or regulatory body
that prohibits or materially impairs either Party from performing its obligations under this Agreement, provided that the Parties
acknowledge and agree that they are entering into this Agreement during the current COVID-19/coronavirus pandemic and have considered
the effects thereof, and such pandemic shall not constitute a “Force Majeure Event”.

 

Section
8.02Notices. All notices under this Agreement shall be in writing. Notices may be served by certified or registered
mail, postage paid with return receipt requested; by private courier, prepaid; by other reliable form of electronic communication;
or personally. Mailed notices shall be deemed delivered five (5) days after mailing, properly addressed. Couriered notices shall
be deemed delivered on the date that the courier warrants that delivery will occur. Electronic communication notices shall be
deemed delivered when receipt is either confirmed by confirming transmission equipment or acknowledged by the addressee or its
office. Personal delivery shall be effective when accomplished. Any Party may change its address by giving notice, in writing,
stating its new address, to the other Party. Subject to the forgoing, notices shall be sent as follows:

 

If
to NutraLife:

 

NutraLife
Biosciences, Inc.

Attn:
Edgar Ward

6601
Lyons Road, Suite L-6

Coconut
Creek, FL 33073

Email:
edgar@nutralifebiosciences.com

 

With
a copy, which shall not constitute notice, to:

 

Anthony
L.G., PLLC

Attn:
John Cacomanolis

625
N. Flagler Drive, Suite 600

West
Palm Beach, FL 33401

Email:
JCacomanolis@anthonypllc.com

 

    	15

     

    

 

If
to the Company, to:

 

27
Health, Inc.

Attn:
Joseph Frontiere

2140
South Dupont Hwy

Camden,
DE 19934

Email:
JFrontiere@gmail.com

 

With
a copy, which shall not constitute notice, to:

 

The
Lonergan Law Firm, LLC

Attn:
Lawrence R. Lonergan, Esq.

96
Park Street

Montclair,
NJ 07042

Email:
llonergan@wlesq.com

 

Section
8.03Entire Agreement. This Agreement sets forth all the promises, covenants, agreements, conditions and understandings
between the Parties, and supersedes all prior and contemporaneous agreements, understandings, inducements or conditions, expressed
or implied, oral or written, except as herein or therein contained.

 

Section
8.04Survival. The provisions of Section 5.04, Article VII and Article VIII of this Agreement, and such additional provisions
as required to give effect thereto, shall survive any termination or expiration hereof, and provided that no expiration or termination
of this Agreement shall excuse a Party for any liability for obligations arising prior to such expiration or termination.

 

Section
8.05Binding Effect; Assignment. This Agreement shall be binding upon the Parties, their heirs, administrators, successors
and assigns. Except as otherwise provided in this Agreement, neither Party may otherwise assign or transfer its interests herein,
or delegate its duties hereunder, without the written consent of the other Party. Any assignment or delegation of duties in violation
of this provision shall be null and void.

 

Section
8.06Amendment. Other than as specifically set forth herein, no amendment, modification, termination, discharge or change
(collectively, “Amendment”) of this Agreement shall be valid and effective, unless the Parties shall unanimously agree
in writing to such Amendment.

 

Section
8.07Further Assurances. Following the Effective Date and until the earlier termination of this Agreement in accordance
with its terms, subject to extension in the event that the Tail Period is applicable, each of the Parties shall, and shall cause
their respective Affiliates to, execute and deliver such additional documents, instruments, conveyances and assurances and take
such further actions as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated
herein.

 

Section
8.08No Waiver. No waiver of any provision of this Agreement shall be effective unless it is in writing and signed by
the Party against whom it is asserted, and any such written waiver shall only be applicable to the specific instance to which
it relates and shall not be deemed to be a continuing or future waiver.

 

    	16

     

    

 

Section
8.09Gender and Use of Singular and Plural. All pronouns shall be deemed to refer to the masculine, feminine, neuter,
singular or plural, as the identity of the Party or Parties, or their personal representatives, successors and assigns may require.

 

Section
8.10Headings. The article and section headings contained in this Agreement are inserted for convenience only and shall
not affect in any way the meaning or interpretation of the Agreement.

 

Section
8.11Governing Law. This Agreement, and any dispute arising out of, relating to, or in connection with this Agreement,
shall be governed by and construed in accordance with the laws of the State of Florida, without giving effect to any choice or
conflict of law provision or rule (whether of the State of Florida or of any other jurisdiction) that would cause the application
of the laws of any jurisdiction other than the State of Florida.

 

Section
8.12Specific Performance. The Parties agree that irreparable damage would occur in the event that any of the provisions
of this Agreement were not performed by them in accordance with the terms hereof or were otherwise breached and that each Party
hereto shall be entitled to an injunction or injunctions, specific performance and other equitable relief to prevent breaches
of the provisions hereof and to enforce specifically the terms and provisions hereof, without the proof of actual damages, in
addition to any other remedy to which they are entitled at law or in equity. Each Party agrees to waive any requirement for the
security or posting of any bond in connection with any such equitable remedy, and agrees that it will not oppose the granting
of an injunction, specific performance or other equitable relief on the basis that (a) the other Party has an adequate remedy
at law, or (b) an award of specific performance is not an appropriate remedy for any reason at law or equity.

 

Section
8.13Enforcement of the Agreement; Jurisdiction; No Jury Trial.

 

	 	(a)	Subject
    to Section 8.12 and Section 8.14, each of the Parties irrevocably agrees that any legal action or proceeding with respect
    to this Agreement and the rights and obligations arising under this Agreement, or for recognition and enforcement of any judgment
    or arbitral award or resolution in respect of this Agreement, shall be brought and determined exclusively in the courts of
    the State of Florida located in Broward County, Florida or in the event (but only in the event) that such courts do not have
    subject matter jurisdiction over such action or proceeding, in the United States District Court sitting in Broward County,
    Florida (the “Selected Courts”). Each of the Parties hereby irrevocably submits with regard to any such action
    or proceeding for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the
    Selected Courts and agrees that it will not bring any action relating to this Agreement or any of the transactions contemplated
    by this Agreement in any court other than the Selected Courts. Each of the Parties hereby irrevocably waives, and agrees not
    to assert, by way of motion, as a defense, counterclaim or otherwise, in any action or proceeding with respect to this Agreement,
    (a) any claim that it is not personally subject to the jurisdiction of the Selected Courts for any reason other than the failure
    to serve in accordance with this Section 8.13; (b) any claim that it or its property is exempt or immune from jurisdiction
    of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior
    to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise); and (c) to the fullest extent
    permitted by law, any claim that (i) the suit, action or proceeding in such court is brought in an inconvenient forum; (ii)
    the venue of such suit, action or proceeding is improper; or (iii) this Agreement, or the subject matter of this Agreement,
    may not be enforced in or by the Selected Courts.

 

    	17

     

    

 

	 	(b)	EACH
    PARTY TO THIS AGREEMENT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT SUCH
    PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY SUIT, ACTION OR OTHER PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF,
    UNDER, RELATING TO OR IN CONNECTION WITH THIS AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT

 

Section
8.14Arbitration. Other than as set forth in Section 8.12, any controversy, claim or dispute arising out of or relating
to this Agreement shall be resolved by arbitration in Coconut Creek, Florida pursuant to then-prevailing rules of the American
Arbitration Association. The arbitration shall be conducted by three arbitrators, with one arbitrator selected by each Party and
the third arbitrator selected by the two arbitrators so selected by the Parties. The arbitrators shall be bound to follow the
applicable Agreement provisions in adjudicating the dispute. It is agreed by both Parties that the arbitrators’ decision
is final, and that no Party may take any action, judicial or administrative, to overturn such decision. The judgment rendered
by the arbitrators may be entered in the Selected Courts. Each Party will pay its own expenses of arbitration and the expenses
of the arbitrators will be equally shared provided that, if in the opinion of the arbitrators any claim, defense, or argument
raised in the arbitration was unreasonable, the arbitrators may assess all or part of the expenses of the other Party (including
reasonable attorneys’ fees) and of the arbitrators as the arbitrators deem appropriate. The arbitrators may not award either
Party punitive or consequential damages.

 

Section
8.15Attorneys’ Fees. If any Party hereto is required to engage in litigation against any other Party, either
as plaintiff or as defendant, in order to enforce or defend any rights under this Agreement, and such litigation results in a
final judgment in favor of such Party (“Prevailing Party”), then the party or parties against whom said final judgment
is obtained shall reimburse the Prevailing Party for all direct, indirect or incidental expenses incurred, including, but not
limited to, all attorneys’ fees, court costs and other expenses incurred throughout all negotiations, trials or appeals
undertaken in order to enforce the Prevailing Party’s rights hereunder.

 

Section
8.16Severability; Expenses. If any term, condition or other provision of this Agreement is determined by a court of
competent jurisdiction to be invalid, illegal or incapable of being enforced by any rule of law or public policy, all other terms,
conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal
substance of the transactions contemplated by this Agreement is not affected in any manner materially adverse to any Party. Upon
such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate
in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in a mutually
acceptable manner in order that the transactions contemplated by this Agreement be consummated as originally contemplated to the
fullest extent possible. Except as otherwise specifically provided in this Agreement, each Party shall be responsible for the
expenses it may incur in connection with the negotiation, preparation, execution, delivery, performance and enforcement of this
Agreement.

 

Section
8.17Parties in Interest. This Agreement shall be binding upon and inure solely to the benefit of each Party, and nothing
in this Agreement, express or implied, is intended to confer upon any other person or entity any rights or remedies of any nature
whatsoever under or by reason of this Agreement other than as specifically set forth herein, including, without limitation, in
Article VII.

 

    	18

     

    

 

Section
8.18Certain Definitions. For purposes of this Agreement, the following terms have the following meanings:

 

	 	(a)	“Affiliate”
    means, with respect to a specified Person, any Person directly or indirectly controlling, controlled by or under common control
    with such Person. As used in this definition, the term “control” means the possession, directly or indirectly,
    of the power to direct or to cause the direction of the management and policies of a Person, whether through ownership of
    voting securities, by contract or otherwise.
	 	 	 
	 	(b)	“Governmental
    Authority” means any federal, state, local or foreign government or political subdivision thereof, or any agency
    or instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental
    regulatory authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization
    or authority have the force of law), or any arbitrator, court or tribunal of competent jurisdiction.
	 	 	 
	 	(c)	“Governmental
    Order” means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or
    with any Governmental Authority.
	 	 	 
	 	(d)	“Law”
    or “Laws” shall mean all present and future laws, as amended from time to time, including, without limitation,
    any rules, orders, ordinances, regulations, statutes, requirements, codes, executive orders, binding restrictions, rules of
    common law, and any judicial interpretations thereof, extraordinary as well as ordinary, of all Governmental Authorities,
    and all rules, regulations, and government orders with respect thereto.
	 	 	 
	 	(e)	“Person”
    means, any individual, corporation, partnership, limited liability company, trust, estate, or other entity, unincorporated
    organization or government, or other agency or political subdivision thereof.

 

Section
8.19Execution in Counterparts, Electronic Transmission. This Agreement may be executed in any number of counterparts,
each of which shall be deemed an original. The signature of any Party which is transmitted by any reliable electronic means such
as, but not limited to, a photocopy, electronically scanned or facsimile machine, for purposes hereof, is to be considered as
an original signature, and the document transmitted is to be considered to have the same binding effect as an original signature
or an original document.

 

[Signatures
appear on following page]

 

    	19

     

    

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.

 

	 	NutraLife
    Biosciences, Inc.
	 	 	 
	 	By:	/s/
    Edgar Ward
	 	Name:	Edgar
    Ward
	 	Title:	Chief
    Executive Officer
	 	 	 
	 	27
    Health, Inc.
	 	 	 
	 	By:	/s/
    Joseph Frontiere
	 	Name:	Joseph
    Frontiere
	 	Title:	Chief
    Executive Officer

 

    	20

     

    

 

EXHIBIT
A

 

Products,
Pricing Structure

 

	Product	 	Price
    to 27 Health	 	MSRP	 	Distributor
    Price	 	Minimum
    Order Quantity
	 	 	 	 	 	 	 	 	 
	Covi-Guard
    2 oz. Oral sanitizer	 	$1.25	 	 	 	 	 	25,000
    units
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 

 

    	21Document

Exhibit 10.1

2013 LONG-TERM INCENTIVE PLAN
2020 ACCOMPLISHMENT AWARD AGREEMENT

United States Cellular Corporation, a Delaware corporation (the "Company"), hereby grants to Laurent C. Therivel (the "Employee") as of July 1, 2020 (the "Grant Date"), an Accomplishment Award (the "Award") with respect to 145,021 shares of Common Stock.  The Award is granted pursuant to the provisions of the United States Cellular Corporation 2013 Long-Term Incentive Plan, as amended from time to time (the “Plan”) and is subject to the restrictions, terms and conditions set forth below.  Capitalized terms not defined herein shall have the meanings specified in the Plan.

1.   Award Subject to Acceptance

The Award shall become null and void unless the Employee accepts the Award and this Award Agreement either electronically by utilizing the Employee’s Company on-line account with Solium Capital, which is accessed at www.solium.com/login, or in paper format which may be obtained by contacting Mary Beth Richardson.

2.   Restriction Period and Forfeiture

(a)  In General.  Except as otherwise provided in this Award Agreement, the Award shall become nonforfeitable and the Restriction Period with respect to the Award shall terminate in the event that during any two calendar-year period commencing no earlier than January 1, 2021 and ending no later than December 31, 2026, the Company achieves both (i) an average total revenue growth rate that exceeds the average total revenue growth rate of the wireless industry (defined as the weighted average wireless revenue growth of AT&T, Inc., Verizon Communications, Inc. and T-Mobile U.S., Inc., or their successors, for that same two-year period) and (ii) an average annual return on capital that exceeds six percent (6%); provided, however, that each of (i) and (ii) (collectively, the “Performance Measures”) must be satisfied during the same two calendar-year period and provided, further, that the Employee must remain continuously employed by the Employers and Affiliates through the last day of that same two calendar-year period.  The December 31 that the conditions set forth in the immediately preceding sentence are achieved and the Award becomes nonforfeitable shall herein be referenced as the “Vesting Date.”

For purposes of this Award Agreement, the Company’s “total revenue” means total operating revenues determined on a consolidated company-wide basis and in a manner consistent with the Company’s presentation of total operating revenues for consolidated external reporting, and the wireless industry’s “total revenue” will be based on each respective company’s definition of wireless operating revenues and will be consistent with external reporting.

For purposes of this Award Agreement, “return on capital” means “Adjusted Net Operating Profit After Tax/Average Capital,” as defined below.

•Adjusted Net Operating Profit After Tax is defined as (Operating income plus Investment income plus Non-operating gains/losses plus Dividend income plus Interest income plus Other income (expense) plus effective interest expense on operating lease payments) multiplied by (1 – Effective Tax Rate).
•Average Capital is defined as total Debt (current & long-term) plus total Equity plus Right of Use Lease Liabilities (current & long-term)

Achievement of the Performance Measures shall be determined and certified by the Committee in writing, and if the Award has become nonforfeitable pursuant to the first paragraph of this Section 2(a), then the Company shall issue to the Employee in a single payment the shares of Common Stock subject to the Award no later than March 15 of the calendar year immediately following the Vesting Date.

Unless earlier forfeited and canceled pursuant to this Section 2, the Award shall terminate in its entirety and be forfeited and canceled effective December 31, 2026, if the Performance Measures have not been achieved as of such date, and the Employee shall have no rights with respect thereto.

(b)  Death.  If the Employee terminates employment with the Employers and Affiliates prior to the Vesting Date by reason of death, then on the date of the Employee’s death one-third of the shares of Common Stock subject to the Award shall become nonforfeitable and the Restriction Period with respect to the Award shall terminate with respect to those shares.  Within sixty (60) days following the date of the Employee’s death, the Company shall issue to the Employee’s designated beneficiary in a single payment the shares of Common Stock subject to the Award that have become nonforfeitable.  On the date of the Employee’s termination by reason of death, the portion of the Award that does not become nonforfeitable pursuant to the first sentence of this Section 2(b) (i.e., two-thirds of the shares of Common Stock subject to the Award) shall be forfeited and shall be canceled by the Company.

(c)  Disability.  If the Employee terminates employment with the Employers and Affiliates prior to the Vesting Date by reason of Disability, then on the date of the Employee’s termination of employment one-third of the shares of Common Stock subject to the Award shall become nonforfeitable and the Restriction Period with respect to the Award shall terminate with respect to those shares.  The Company shall issue the shares of Common Stock subject to the Award that have become nonforfeitable in a single payment within sixty (60) days following the date of the Employee’s termination of employment.  On the date of the Employee’s termination by reason of Disability, the portion of the Award that does not become nonforfeitable pursuant to the first sentence of this Section 2(c) (i.e., two-thirds of the shares of Common Stock subject to the Award) shall be forfeited and shall be canceled by the Company.  For purposes of this Award Agreement, “Disability” shall mean a total physical disability which, in the Committee’s judgment, prevents the Employee from performing substantially his or her employment duties and responsibilities for a continuous period of at least six months.

(d)  Other Termination of Employment.  If the Employee terminates employment with the Employers and Affiliates prior to the Vesting Date for any reason other than death or Disability, then on the date of the Employee’s termination of employment the Award shall be forfeited and shall be canceled by the Company.

(e)  Forfeiture of Award and Award Gain upon Competition, Misappropriation, Solicitation or Disparagement.  Notwithstanding any other provision herein, if the Employee engages in (i) Competition (as defined in this Section 2(e) below); (ii) Misappropriation (as defined in this Section 2(e) below); (iii) Solicitation (as defined in this Section 2(e) below) or (iv) Disparagement (as defined in this Section 2(e) below), in each case as determined by the Company in its sole discretion, then (i) on the date of such Competition, Misappropriation, Solicitation or Disparagement, the Award immediately shall be forfeited and shall be canceled by the Company and (ii) in the event that the Award became nonforfeitable within the twelve months immediately preceding such Competition, Misappropriation, Solicitation or Disparagement, the Employee shall pay the Company, within five business days of receipt by the Employee of a written demand therefore, an amount in cash determined by multiplying the number of shares of Common Stock subject to the Award (without reduction for any shares of Common Stock delivered by the Employee or withheld by the Company pursuant to Section 4.3) by the Fair Market Value of a share of Common Stock on the date that the Award was paid.  The Employee acknowledges and agrees that the Award, by encouraging stock ownership and thereby increasing an employee’s proprietary interest in the Company’s success, is intended as an incentive to participating employees to remain in the employ of the Employers or an Affiliate.  The Employee acknowledges and agrees that this Section 2(e) is therefore fair and reasonable, and not a penalty.

The Employee may be released from the Employee’s obligations under this Section 2(e) only if and to the extent the Committee determines in its sole discretion that such release is in the best interests of the Company.

The Employee agrees that by accepting this Award Agreement the Employee authorizes the Employers and any Affiliate to deduct any amount owed by the Employee pursuant to this Section 2(e) from any amount payable by the Employers or any Affiliate to the Employee, including, without limitation, any amount payable to the Employee as salary, wages, vacation pay or bonus.  The Employee further agrees to execute any documents at the time of setoff required by the Employers and any Affiliate in order to effectuate the setoff.  This right of setoff shall not be an exclusive remedy and an Employer’s or an Affiliate’s election not to exercise this right of setoff with respect to any amount payable to the Employee shall not constitute a waiver of this right of setoff with respect to any other amount payable to the Employee or any other remedy.  Should the Employers and/or any Affiliate institute a legal action against the Employee to recover the amounts due, the Employee agrees to reimburse the Employers and/or any Affiliate for their reasonable attorneys’ fees and litigation costs incurred in recovering such amounts from the Employee.

For purposes of this Award Agreement, “Competition” shall mean that the Employee, directly or indirectly, individually or in conjunction with any Person, during the Employee’s employment with the Employers and the Affiliates and for the twelve months after the termination of that employment for any reason, other than on any Employer’s or Affiliate’s behalf (i) has contact with any customer of an Employer or Affiliate or with any prospective customer which has been contacted or solicited by or on behalf of an Employer or Affiliate for the purpose of soliciting or selling to such customer or prospective customer the same or a similar (such that it could substitute for) product or service provided by an Employer or Affiliate during the Employee’s employment with the Employers and the Affiliates; or (ii) becomes employed in the business or engages in the business of providing wireless, telephone, broadband or information technology products or services in any county or county contiguous to a county in which an Employer or Affiliate provided such products or services during the Employee’s employment with the Employers and the Affiliates or had plans to do so within the twelve month period immediately following the Employee’s termination of employment.

For purposes of this Award Agreement, “Misappropriation” shall mean that the Employee (i) uses Confidential Information (as defined below) for the benefit of anyone other than the Employers or an Affiliate, as the case may be, or discloses the Confidential Information to anyone not authorized by the Employers or an Affiliate, as the case may be, to receive such information; (ii) upon termination of employment, makes any summaries of, takes any notes with respect to or memorizes any Confidential Information or takes any Confidential Information or reproductions thereof from the facilities of the Employers or an Affiliate or (iii) upon termination of employment or upon the request of the Employers or an Affiliate, fails to return all Confidential Information then in the Employee’s possession.  For the avoidance of doubt, “Misappropriation” does not include disclosure of Confidential Information to a governmental regulatory agency, such as the U.S. Securities and Exchange Commission, provided that the Employee informs the agency that the Employers and/or Affiliates deem the information to be confidential.  “Confidential Information” shall mean any confidential and proprietary drawings, reports, sales and training manuals, customer lists, computer programs and other material embodying trade secrets or confidential technical, business, or financial information of the Employers or an Affiliate.

For purposes of this Award Agreement, “Solicitation” shall mean that the Employee, directly or indirectly, individually or in conjunction with any Person, during the Employee’s employment with the Employers and the Affiliates and for the twelve months after the termination of that employment for any reason, other than on any Employer’s or Affiliate’s behalf, solicits, induces or encourages (or attempts to solicit, induce or encourage) any individual away from any Employer’s or Affiliate’s employ or from the faithful discharge of such individual’s contractual and fiduciary obligations to serve the Employers’ and Affiliates’ interests with undivided loyalty.

For purposes of this Award Agreement, “Disparagement” shall mean that the Employee has made a statement (whether oral, written or electronic) to any Person other than to an officer of an Employer or an Affiliate that disparages or demeans the Employers, any Affiliate, or any of their respective owners, directors, officers, employees, products or services.  For the avoidance of doubt, “Disparagement” does not include making truthful statements to any governmental regulatory agency or to testimony in any legal proceeding.

3.    Change in Control

(a)  In General.  Notwithstanding any provision in the Plan or any other provision of this Award Agreement, in the event of a Change in Control, the Board (as constituted prior to such Change in Control) may in its discretion, but shall not be required to, make such adjustments to the Award as it deems appropriate, including, without limitation:  (i) causing the Award to become nonforfeitable in whole or in part; and/or (ii) causing the Restriction Period with respect to the Award to lapse in full or in part and payment of the Award, to the extent the Restriction Period has lapsed, to occur within sixty (60) days following the occurrence of the Change in Control (the “Change in Control Payment Period”); and/or (iii) substituting for some or all of the shares of Common Stock subject to the Award the number and class of shares into which each outstanding share of Common Stock shall be converted pursuant to the Change in Control, with an appropriate and equitable adjustment to the Award as determined by the Committee in accordance with Section 4.5 below and/or (iv) requiring that the Award, in whole or in part, be surrendered to the Company by the holder thereof and be immediately canceled by the Company and providing that the holder of the Award receive, within the Change in Control Payment Period, (X) a cash payment in an amount equal to the number of shares of Common Stock then subject to the portion of the Award surrendered, to the extent the Restriction Period on the Award has lapsed or will lapse pursuant to this Section 3(a), multiplied by the Fair Market Value of a share of Common Stock as of the date of the Change in Control; (Y) shares of capital stock of the corporation resulting from or succeeding to the business of the Company pursuant to the Change in Control, or a parent corporation thereof, having a fair market value not less than the amount determined under clause (X) above; or (Z) a combination of the payment of cash pursuant to clause (X) above and the issuance of shares pursuant to clause (Y) above.

(b)  Definition of Change in Control.  For purposes of the Plan and this Award Agreement, a "Change in Control" shall mean: 

(1)  the acquisition by any Person, including any "person" within the meaning of section 13(d)(3) or 14(d)(2) of the Exchange Act, of beneficial ownership within the meaning of Rule 13d-3 promulgated under the Exchange Act, of the then outstanding securities of the Company (the “Outstanding Voting Securities”) (x) having sufficient voting power of all classes of capital stock of the Company to elect at least 50% or more of the members of the Board or (y) having 50% or more of the combined voting power of the Outstanding Voting Securities entitled to vote generally on matters (without regard to the election of directors), excluding, however, the following:  (i) any acquisition directly from the Company or an Affiliate (excluding any acquisition resulting from the exercise of an exercise, conversion or exchange privilege, unless the security being so exercised, converted or exchanged was acquired directly from the Company or an Affiliate), (ii) any acquisition by the Company or an Affiliate, (iii) any acquisition by an employee benefit plan (or related trust) sponsored or maintained by the Company or an Affiliate, (iv) any acquisition by any corporation pursuant to a transaction which complies with clauses (i), (ii) and (iii) of subsection (3) of this Section 3(b), or (v) any acquisition by the following Persons:  (A) any child of LeRoy T. Carlson or the spouse of any such child, (B) any grandchild of LeRoy T. Carlson, including any child adopted by any child of LeRoy T. Carlson, or the spouse of any such grandchild, (C) the estate of any of the Persons described in clause (A) or (B), (D) any trust or similar arrangement (including any acquisition on behalf of such trust or similar arrangement by the trustees or similar Persons) provided that all of the current beneficiaries of such trust or similar arrangement are Persons described in clause (A) or (B) or their lineal descendants, or (E) the voting trust which expires on June 30, 2035, or any successor to such voting trust, including the trustees of such voting trust on behalf of such voting trust (all such Persons, collectively, the "Exempted Persons");

(2)  individuals who, as of March 15, 2016, constitute the Board (the "Incumbent Board") cease for any reason to constitute at least a majority of such Board; provided that any individual who becomes a director of the Company subsequent to March 15, 2016, and whose election or nomination for election by the Company's stockholders was approved by the vote of at least a majority of the directors then comprising the Incumbent Board, shall be deemed a member of the Incumbent Board;

(3)  consummation of a reorganization, merger or consolidation or sale or other disposition of all or substantially all of the assets of the Company (a "Corporate Transaction"), excluding, however, a Corporate Transaction pursuant to which (i) all or substantially all of the Persons who are the beneficial owners of the Outstanding Voting Securities immediately prior to such Corporate Transaction will beneficially own, directly or indirectly, (x) sufficient voting power to elect at least a majority of the members of the board of directors of the corporation resulting from the Corporate Transaction and (y) more than 50% of the combined voting power of the outstanding securities which are entitled to vote generally on matters (without regard to the election of directors) of the corporation resulting from such Corporate Transaction (including in each of clauses (x) and (y), without limitation, a corporation which as a result of such transaction owns, either directly or indirectly, the Company or all or substantially all of the Company's assets), in substantially the same proportions relative to each other as the shares of Outstanding Voting Securities are owned immediately prior to such Corporate Transaction, (ii) no Person (other than the following Persons:  (v) the Company or an Affiliate, (w) any employee benefit plan (or related trust) sponsored or maintained by the Company or an Affiliate, (x) the corporation resulting from such Corporate Transaction, (y) the Exempted Persons, and (z) any Person which beneficially owned, immediately prior to such Corporate Transaction, directly or indirectly, 50% or more of the Outstanding Voting Securities) will beneficially own, directly or indirectly, 50% or more of the combined voting power of the outstanding securities of such corporation entitled to vote generally on matters (without regard to the election of directors) and (iii) individuals who were members of the Incumbent Board will constitute at least a majority of the members of the board of directors of the corporation resulting from such Corporate Transaction; or

(4)  approval by the stockholders of the Company of a plan of complete liquidation or dissolution of the Company.

4.   Additional Terms and Conditions of Award

4.1.  Transferability of Award.  Except pursuant to a beneficiary designation on a form prescribed by the Company and effective on the Employee's death, the Award may not be sold, transferred, assigned, pledged, hypothecated, encumbered or otherwise disposed of (whether by operation of law or otherwise) or be subject to execution, attachment or similar process.  Upon any attempt to so sell, transfer, assign, pledge, hypothecate, encumber or otherwise dispose of the Award, the Award and all rights hereunder shall immediately become null and void.

By accepting the Award, the Employee agrees that if all beneficiaries designated on a form prescribed by the Company predecease the Employee or, in the case of corporations, partnerships, trusts or other entities which are designated beneficiaries, are terminated, dissolved, become insolvent or are adjudicated bankrupt prior to the date of the Employee’s death, or if the Employee fails to properly designate a beneficiary on a form prescribed by the Company (including by failure to return such form to the appropriate Company representative during the Employee’s lifetime), then the Employee hereby designates the following Persons in the order set forth herein as the Employee’s beneficiary or beneficiaries:  (i) the Employee’s spouse, if living, or if none, (ii) the Employee’s then living descendants, per stirpes, or if none, (iii) the Employee’s estate.

4.2.  Investment Representation.  The Employee hereby represents and covenants that (a) any shares of Common Stock acquired upon the lapse of restrictions with respect to the Award will be acquired for investment and not with a view to the distribution thereof within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), unless such acquisition has been registered under the Securities Act and any applicable state securities laws; (b) any subsequent sale of any such shares shall be made either pursuant to an effective registration statement under the Securities Act and any applicable state securities laws, or pursuant to an exemption from registration under the Securities Act and such state securities laws; and (c) if requested by the Company, the Employee shall submit a written statement, in a form satisfactory to the Company, to the effect that such representation is true and correct as of the date of acquisition of any shares hereunder or is true and correct as of the date of sale of any such shares, as applicable.  As a condition precedent to the issuance or delivery to the Employee of any shares subject to the Award, the Employee shall comply with all regulations and requirements of any regulatory authority having control of or supervision over the issuance or delivery of the shares and, in connection therewith, shall execute any documents which the Committee shall in its sole discretion deem necessary or advisable.

4.3.  Tax Withholding.  The Employee timely shall pay to the Company such amount as the Company may be required, under all applicable federal, state, local or other laws or regulations, to withhold and pay over as income or other withholding taxes (the "Required Tax Payments") with respect to the Award.  The Employee may elect to satisfy his or her obligation to advance the Required Tax Payments by (a) authorizing the Company to withhold whole shares of Common Stock which otherwise would be delivered to the Employee pursuant to the Award, having an aggregate Fair Market Value determined as of the date the obligation to withhold or pay taxes arises in connection with the Award or (b) delivery (either actual delivery or by attestation procedures established by the Company) to the Company of previously-owned whole shares of Common Stock, having an aggregate Fair Market Value determined as of the date the obligation to withhold or pay taxes arises in connection with the Award.  Shares of Common Stock to be withheld or delivered may not have an aggregate Fair Market Value in excess of the amount determined by applying the minimum statutory withholding rate.  Unless other arrangements have been made to the Company’s satisfaction, any fraction of a share of Common Stock which would be required to pay the Required Tax Payments shall be disregarded and the remaining amount due shall be paid in cash by the Employee.  The Employee agrees that if by the pay period that immediately follows the date that the Restriction Period with respect to the Award terminates, no cash payment attributable to any such fractional share shall have been received by the Company, then the Employee hereby authorizes the Company to deduct such cash payment from any amount payable by the Company or any Affiliate to the Employee, including without limitation any amount payable to the Employee as salary or wages.

The Employee agrees that the authorization set forth in this Section 4.3 with respect to deducting cash payments from future amounts payable may be reauthorized via electronic means determined by the Company.  The Employee may revoke this authorization by written notice to the Company prior to any such deduction.

4.4.  Award Confers No Rights as a Stockholder.  The Employee shall not be entitled to any privileges of ownership with respect to the shares of Common Stock subject to the Award unless and until the restrictions on the Award lapse and the Employee becomes a stockholder of record with respect to such shares.

4.5.  Adjustment.  In the event of any equity restructuring (within the meaning of Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation—Stock Compensation) that causes the per share value of shares of Common Stock to change, such as a stock dividend, stock split, spinoff, rights offering or recapitalization through an extraordinary dividend, the number and class of shares of Common Stock subject to the Award shall be appropriately and equitably adjusted by the Committee.  In the event of any other change in corporate capitalization, including a merger, consolidation, reorganization or partial or complete liquidation of the Company, such adjustment described in the foregoing sentence may be made as determined to be appropriate and equitable by the Committee to prevent dilution or enlargement of rights of participants.  In either case, such adjustment shall be final, binding and conclusive.  If such adjustment would result in a fractional share being subject to the Award, the Company shall pay the holder of the Award, on the date that the shares with respect to the Award are issued, an amount in cash determined by multiplying (i) the fraction of such share (rounded to the nearest hundredth) by (ii) the Fair Market Value of a share on the date that the Restriction Period with respect to the Award terminates.

4.6.  Compliance with Applicable Law.  The Award is subject to the condition that if the listing, registration or qualification of the shares of Common Stock subject to the Award upon any securities exchange or under any law, the consent or approval of any governmental body or the taking of any other action is necessary or desirable as a condition of, or in connection with, the delivery of shares, such shares will not be delivered unless such listing, registration, qualification, consent, approval or other action shall have been effected or obtained, free of any conditions not acceptable to the Company.  The Company agrees to use reasonable efforts to effect or obtain any such listing, registration, qualification, consent, approval or other action.

4.7.  Delivery of Shares.  On the date of payment of the Award, the Company shall deliver or cause to be delivered to the Employee the shares of Common Stock subject to the Award.  The Company may require that the shares of Common Stock delivered pursuant to the Award bear a legend indicating that the sale, transfer or other disposition thereof by the Employee is prohibited except in compliance with the Securities Act of 1933, as amended, and the rules and regulations thereunder.  The holder of the Award shall pay all original issue or transfer taxes and all fees and expenses incident to such delivery, unless the Company in its discretion elects to make such payment.

4.8.  Award Confers No Rights to Continued Employment or Service.  In no event shall the granting of the Award or the acceptance of this Award Agreement and the Award by the Employee give or be deemed to give the Employee any right to continued employment by or service with the Company or any of its subsidiaries or affiliates.

4.9.  Decisions of Committee.  The Committee shall have the right to resolve all questions which may arise in connection with the Award.  Any interpretation, determination or other action made or taken by the Committee regarding the Plan or this Award Agreement shall be final, binding and conclusive.

4.10.  Company to Reserve Shares.  The Company shall at all times prior to the cancellation of the Award reserve and keep available, either in its treasury or out of its authorized but unissued shares of Common Stock, the full number of shares subject to the Award from time to time.

4.11.  Award Agreement Subject to the Plan.  This Award Agreement is subject to the provisions of the Plan, and shall be interpreted in accordance therewith.  The Employee hereby acknowledges receipt of a copy of the Plan.

4.12.  Award Subject to Clawback.  The Award and any shares of Common Stock delivered pursuant to the Award are subject to forfeiture, recovery by the Company or other action pursuant to any clawback or recoupment policy which the Company may adopt from time to time, including without limitation any such policy which the Company may be required to adopt under the Dodd-Frank Wall Street Reform and Consumer Protection Act and implementing rules and regulations thereunder, or as otherwise required by law.

5.   Miscellaneous Provisions

5.1.  Successors.  This Award Agreement shall be binding upon and inure to the benefit of any successor or successors of the Company and any Person or Persons who shall, upon the death of the Employee, acquire any rights hereunder.

5.2.  Notices.  All notices, requests or other communications provided for in this Award Agreement shall be made in writing either (a) by actual delivery to the party entitled thereto, (b) by mailing in the United States mails to the last known address of the party entitled thereto, via certified or registered mail, postage prepaid and return receipt requested, (c) by electronic mail, utilizing notice of undelivered electronic mail features or (d) by telecopy with confirmation of receipt.  The notice, request or other communication shall be deemed to be received (a) in case of delivery, on the date of its actual receipt by the party entitled thereto, (b) in case of mailing by certified or registered mail, five days following the date of such mailing, (c) in case of electronic mail, on the date of mailing but only if a notice of undelivered electronic mail is not received or (d) in case of telecopy, on the date of confirmation of receipt.

5.3.  Governing Law.  The Award, this Award Agreement and the Plan, and all determinations made and actions taken pursuant thereto, to the extent otherwise not governed by the Code or the laws of the United States, shall be governed by the laws of the State of Delaware and construed in accordance therewith without giving effect to principles of conflicts of laws.

5.4.  Compliance with Section 409A of the Code.  It is intended that the Award, this Award Agreement and the Plan be exempt from the requirements of section 409A of the Code to the maximum extent possible.

						
	UNITED STATES CELLULAR CORPORATION
		
	By:	/s/ LeRoy T. Carlson, Jr.
		LeRoy T. Carlson, Jr.
		Chairman

(Accept grant electronically via Employee’s account at www.solium.com/login)

			
	IMPORTANT NOTICE-PLEASE READ
If this is your first grant of stock options, restricted stock units or a performance/accomplishment award from U.S. Cellular®, please note that you must submit a beneficiary designation form to U.S. Cellular®, Attn: Compensation Department, 8410 W. Bryn Mawr Avenue, Chicago, IL 60631. The form can be printed from your account at www.solium.com/login under the “Personal Profile and Passwords” tab, “Miscellaneous Account Information” section. You also may elect at any time to change a previously-designated beneficiary for your stock options, restricted stock units and performance/accomplishment awards by completing and submitting to U.S. Cellular a new beneficiary designation form.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]